Sunday, 25 Oct 2026
Empowering Chinese Pharma’s Global Expansion
Contact US
Home
About US
Policy Hub
Categories
Drug
Company
Deals
Policy / Regulatory
Medical Device
R&D
Legal / IP
Digital
Privacy Policy
Contact US
My News
Cancer
Clinical trial approval / initiation
Product approvals
Clinical trial results
Finance
ADC / XDC
Finanical Reports
Biotech
Market approval filings
PD-1/L1
Read History
Search
Pages
Home
Blog Index
POLICY HUB
Contact Us
Personalized
Read History
Categories
Company
Drug
Policy / Regulatory
Medical Device
R&D
Digital
Legal / IP
Deals
Have an existing account?
Sign In
Follow US
Company
Drug
Luye Pharma’s BA1302 Receives FDA Orphan Drug Designation for Lung and Pancreatic Cancer
March 27, 2025
Company
Deals
Insilico Medicine Collaborates with Mabwell Bio to Enhance ADC R&D with AI
March 27, 2025
Company
Deals
Bayer Inks Licensing Deal for Suzhou Puhe’s PRMT5 Inhibitor, BAY 3713372
March 27, 2025
Company
Drug
AstraZeneca’s Calquence Approved by NMPA for CLL/SLL Treatment
March 27, 2025
Company
Medical Device
Shanghai ZJ Bio-Tech’s HCV Nucleic Acid Test Kit Receives NMPA Approval
March 27, 2025
Company
Deals
Shanghai RAAS Plans RMB4.2 Billion Acquisition of Nanyue BioPharming to Boost Plasma Resources
March 27, 2025
Company
Drug
Sichuan Huiyu Pharmaceutical Wins Marketing Approvals in Italy, Portugal, Saudi Arabia
March 27, 2025
Company
Deals
Merck KGaA Partners with Roche to Commercialize Tepmetko in China
March 26, 2025
Company
Hospital
China Resources Medical Holdings Reports 2024 Revenue of RMB9.86 Billion Amid Net Profit Surge
March 26, 2025
Company
Drug
GSK’s Blujepa Approved by FDA for Uncomplicated Urinary Tract Infections
March 26, 2025
Company
Drug
Guangzhou Doublle Bioproduct Receives IND Approval for E101 in Type 2 Diabetes
March 26, 2025
Company
WuXi Biologics Reports 9.6% Revenue Growth in 2024, Expanding CRDMO Services
March 26, 2025
1
2
…
4
5
6
7
8
…
31
32
Welcome to Fineline Cube!
Username or Email Address
Password
Remember me
Lost your password?
